喵咪社区

Home / 喵咪社区 ALS Center of Excellence Clinical Trials

喵咪社区 ALS Center of Excellence Clinical Trials

#Disease CategoryTitleClinicalTrials.gov StatusClinicalTrials.gov Link
1ALSPerpetual Multi-Center, Multi-Regimen Clinical Trial Evaluating the Safety and Efficacy of Investigational Products for the Treatment of ALS (Regimen G: DNL343)Completed
2ALSPerpetual Multi-Center, Multi-Regimen Clinical Trial Evaluating the Safety and Efficacy of Investigational Products for the Treatment of ALS (Regimen F: ABBV-CLS-7262)Completed
3ALSA phase 2, randomized, double-blind, placebo-controlled parallel group study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) over 40 weeks followed by an Open-label Extension (ASTRALS)Recruiting
4ALSA prospective, multicenter, randomized, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo in combination with Riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)Study is on hold
5ALSA Two-part Phase 3b Randomized, Double-Blind, Placebo-Controlled, Followed by Open Label Extension, Multicenter Study of the Efficacy and Safety of NurOwn in Participants with Amyotrophic Lateral SclerosisNot open for enrollment yet 
6ALSA prospective, multicenter, randomized, double-blind, placebo-controlled, parallel groups, phase 3 trial to compare the efficacy and safety of masitinib in combination with standard of care versus placebo in combination with standard of care in the treatment of patients suffering from amyotrophic lateral sclerosis (ALS)Not open for enrollment yet 
7ALSOxidative Markers and Efficacy in ALS /MND Phenotypes treated with EdaravoneRecruiting
8ALSCellular re-programming to study neurodegenerative diseases, including ALS and FTD, using patient鈥檚 induced pluripotent stem cells [Pending]
9Myasthenia GravisA randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patients with generalized myasthenia gravis, followed by an open label extension phase(Novartis CLOU0644O12301)Recruiting
10Myasthenia GravisA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study with an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia GravisRecruiting
11Myasthenia GravisEfficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients with Symptomatic Generalized Myasthenia Gravis (NIMBLE)Enrollment is closed
12CIDPA Phase 3, double-blind, placebo-controlled study evaluating efficacy and safety of riliprubart in participants with refractory chronic inflammatory demyelinating polyneuropathyRecruiting
13CIDPA Phase 3, double-blind, placebo-controlled study evaluating efficacy and safety of riliprubart in participants with refractory chronic inflammatory demyelinating polyneuropathy(MOBILIZE study)Recruiting
14CIDPA Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Active, not recruiting
15CIDPA Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants with Chronic Inflammatory Demyelinating Polyneuropathy (VITALIZE study) Recruiting
16IIMA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory MyopathyEnrollment is closed
     
17IBMAn Open-label, Multicenter Study to Evaluate the Long-term Safety and Efficacy of Ulviprubart (ABC008) in Subjects Who Have Completed a Trial of Ulviprubart for the Treatment of Inclusion Body MyositisActive, not recruiting
18IBMA Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body MyositisActive, not recruiting